89 related articles for article (PubMed ID: 8334560)
1. DNA analysis and persistent hypercalcitoninemia in medullary thyroid carcinoma.
Jeng TK; Lee CH; Wang HC; Chiu JW; Lui WY
Zhonghua Yi Xue Za Zhi (Taipei); 1993 May; 51(5):340-4. PubMed ID: 8334560
[TBL] [Abstract][Full Text] [Related]
2. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.
van Heerden JA; Grant CS; Gharib H; Hay ID; Ilstrup DM
Ann Surg; 1990 Oct; 212(4):395-400; discussion 400-1. PubMed ID: 2222011
[TBL] [Abstract][Full Text] [Related]
3. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
4. Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies.
Kim JM; Chung KW; Kim SW; Choi SH; Min HS; Kim JN; Won WJ; Kim SK; Lee JI; Chung JH; Kim SW
Head Neck; 2010 Jan; 32(1):68-75. PubMed ID: 19536770
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence.
Cho YY; Jang HW; Jang JY; Kim TH; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Head Neck; 2016 Oct; 38(10):1501-8. PubMed ID: 27062421
[TBL] [Abstract][Full Text] [Related]
6. Mild persistent hypercalcitoninemia after total thyroidectomy in patients with papillary thyroid carcinoma.
Yokoi K; Imai T; Shibata A; Hibi Y; Kikumori T; Funahashi H; Nakao A
Endocr J; 2003 Aug; 50(4):453-8. PubMed ID: 14599120
[TBL] [Abstract][Full Text] [Related]
7. Biochemical results of reoperations for medullary thyroid carcinoma.
Fernandez Vila JM; Peix JL; Mandry AC; Mezzadri NA; Lifante JC
Laryngoscope; 2007 May; 117(5):886-9. PubMed ID: 17473689
[TBL] [Abstract][Full Text] [Related]
8. [Type of surgery for 147 patients with medullary carcinoma of the thyroid].
Huang CP; Zhu YX; Tian AL
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):490-2. PubMed ID: 14575577
[TBL] [Abstract][Full Text] [Related]
9. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels.
Tisell LE; Dilley WG; Wells SA
Surgery; 1996 Jan; 119(1):34-9. PubMed ID: 8560383
[TBL] [Abstract][Full Text] [Related]
10. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
[TBL] [Abstract][Full Text] [Related]
11. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients.
Chambon G; Alovisetti C; Idoux-Louche C; Reynaud C; Rodier M; Guedj AM; Chapuis H; Lallemant JG; Lallemant B
J Clin Endocrinol Metab; 2011 Jan; 96(1):75-81. PubMed ID: 20881258
[TBL] [Abstract][Full Text] [Related]
12. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
13. Persistent hypercalcitoninemia in patients with medullary thyroid cancer: a therapeutic approach based on selective venous sampling for calcitonin.
Medina-Franco H; Herrera MF; López G; Tielve-Campillo M; Sierra M; Lozano-Salazar RR; González O
Rev Invest Clin; 2001; 53(3):212-7. PubMed ID: 11496707
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
15. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
Skinner MA; Wells SA
Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
[TBL] [Abstract][Full Text] [Related]
16. Review analysis of medullary carcinoma of the thyroid: a 15-year Indian experience.
Dorairajan N; Siddharth D; Kanna S
Int Surg; 2006; 91(3):162-7. PubMed ID: 16845858
[TBL] [Abstract][Full Text] [Related]
17. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia.
Chi DD; Moley JF
Surg Oncol Clin N Am; 1998 Oct; 7(4):681-706. PubMed ID: 9735129
[TBL] [Abstract][Full Text] [Related]
19. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
20. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
Elisei R; Bottici V; Luchetti F; Di Coscio G; Romei C; Grasso L; Miccoli P; Iacconi P; Basolo F; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2004 Jan; 89(1):163-8. PubMed ID: 14715844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
